In 2023, the investigational antibody–drug conjugate SAR408701 (tusamitab revtamab) advanced to Phase III clinical trials for CEACAM5-positive NSCLC, marking a significant milestone in targeted therapy development (Figure 14) [137]. This evidence concerns the gene CEACAM5 and non-small cell lung carcinoma.